Frontiers in Veterinary Science (Sep 2024)

Evaluation of protective immune responses induced by DNA vaccines encoding Echinococcus granulosus EgM123 protein in Beagle dogs

  • Ning Wang,
  • Ning Wang,
  • Ning Wang,
  • Jinwen Xian,
  • Jinwen Xian,
  • Jinwen Xian,
  • Pengpeng Zhao,
  • Pengpeng Zhao,
  • Pengpeng Zhao,
  • Wenqing Zhao,
  • Wenqing Zhao,
  • Wenqing Zhao,
  • Na Pu,
  • Na Pu,
  • Na Pu,
  • Xinyue Jia,
  • Xinyue Jia,
  • Xinyue Jia,
  • Yanyan Zhang,
  • Xinwen Bo,
  • Xinwen Bo,
  • Xinwen Bo,
  • Zhengrong Wang,
  • Zhengrong Wang

DOI
https://doi.org/10.3389/fvets.2024.1444741
Journal volume & issue
Vol. 11

Abstract

Read online

IntroductionEchinococcus granulosus, known as cystic echinococcosis, is a prominent zoonotic parasitic disease of significant global concern. The definitive hosts serves as the primary reservoir for the transmission of echinococcosis, as well as a main factor in the prevention and control of the disease. Unfortunately, there is currently no commercially available vaccine for these hosts. Nevertheless, DNA vaccines show potential as a feasible strategy for the control and management of parasitic diseases.MethodsIn this study, the EgM123 antigen was selected for its well-documented immunogenic properties to develop a DNA vaccine aimed at combating E. granulosus infection in canines.ResultsThe results showed a marked increase in IgG levels in the group vaccinated with pVAX1-EgM123 DNA compared to the PBS group. Additionally, the cytokines IL-1, IFN-γ, IL-4, and IL-6 were significantly upregulated in the pVAX1-EgM123 DNA vaccine group. Furthermore, in comparison to the PBS control group, the EgM123 DNA vaccine group exhibited a notable 87.85% reduction in worm burden and a 65.00% inhibition in segment development.DiscussionThese findings indicate that the pVAX1-EgM123 DNA vaccine shows promising immunogenicity, successfully eliciting a targeted immune response in canines. Moreover, it significantly diminishes the worm burden and hinders the progression of tapeworms in the pVAX1-EgM123 DNA vaccine group. These findings suggest that the pVAX1-EgM123 DNA vaccine holds promise as a potential candidate vaccine for combating E. granulosus infection in dogs.

Keywords